Risk factors for infection with colistin-resistant gram-negative microorganisms: a multicenter study

dc.contributor.authorYilmaz, Gul R.
dc.contributor.authorDizbay, Murat
dc.contributor.authorGuven, Tumer
dc.contributor.authorPullukcu, Husnu
dc.contributor.authorTasbakan, Meltem
dc.contributor.authorGuzel, Ozlem Tunccan
dc.contributor.authorTasyaran, Mehmet A.
dc.date.accessioned2026-08-12T17:32:58Z
dc.date.issued2016
dc.departmentFırat Üniversitesi
dc.description.abstractBACKGROUND: Knowing risk factors for colistin resistance is important since colistin is the only remaining choice for the treatment of infections caused by multi-drug resistant microorganisms. OBJECTIVE: Evaluate risk factors associated with infection by colistin-resistant microorganisms. DESIGN: Retrospective study. SETTINGS: Tertiary healthcare centers. PATIENTS AND METHODS: An e-mail including the title and purpose of the study was sent to 1500 infectious disease specialists via a scientific and social web portal named Infeksiyon Dunyasi (Infection World). Demographic and clinical data was requested from respondents. MAIN OUTCOME MEASURE(S): Colistin-resistance. RESULTS: Eighteen infectious disease specialists from twelve tertiary care centers responded to the invitation. Data was collected on 165 patients, 56 cases (39.9%) and 109 (66.0%) age-and sex-matched controls. The colistin-resistant microorganisms isolated from cases were 29 Acinetobacter baumannii (51.8%), 18 Pseudomonas aeruginosa (32.1%) and 9 Klebsiella spp. Colistin, carbapenem, and quinolone use in the last three months were risk factors for colistin resistance in the univariate analysis. Previous quinolone use in the last three months (P=.003; RR: 3.2; 95% CI: 1.5-6,7) and previous colistin use in the last three months (P=.001; RR: 3.6; 95% CI: 1.63-7.99) were significant risk factors in the multivariate analysis. CONCLUSION: Clinicians should limit the use of quinolones and remain aware of the possibility of resistance developing during colistin use. LIMITATIONS: The lack of a heteroresistance analysis on the isolates. No data on use of a loading dose or the use of colistin in combination.
dc.identifier.doi10.5144/0256-4947.2016.216
dc.identifier.endpage222
dc.identifier.issn0256-4947
dc.identifier.issn1319-9226
dc.identifier.issue3
dc.identifier.orcid0000-0003-4120-0781
dc.identifier.orcid0000-0001-5187-7388
dc.identifier.orcid0000-0003-3918-564X
dc.identifier.orcid0000-0002-9983-0308
dc.identifier.orcid0000-0003-3823-4454
dc.identifier.orcid0000-0002-0436-7550
dc.identifier.pmid27236394
dc.identifier.scopus2-s2.0-84981266874
dc.identifier.scopusqualityQ2
dc.identifier.startpage216
dc.identifier.urihttps://doi.org/10.5144/0256-4947.2016.216
dc.identifier.urihttps://hdl.handle.net/11508/56843
dc.identifier.volume36
dc.identifier.wosWOS:000384907900008
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherK Faisal Spec Hosp Res Centre
dc.relation.ispartofAnnals of Saudi Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subject2-Component Regulatory System
dc.subjectCritically-Ill Patients
dc.subjectKlebsiella-Pneumoniae
dc.subjectPseudomonas-Aeruginosa
dc.subjectCystic-Fibrosis
dc.subjectPolymyxin-B
dc.subjectAcinetobacter
dc.subjectSusceptibility
dc.subjectMethanesulfonate
dc.subjectHeteroresistance
dc.titleRisk factors for infection with colistin-resistant gram-negative microorganisms: a multicenter study
dc.typeArticle

Dosyalar